Health spending allocations reflect the political economy of health systems as much as the evidence base for effective interventions.
How Health Spending Is Actually Determined
Health spending allocations are determined through a political economy only partly shaped by evidence about what produces the best health outcomes per unit of investment. The political economy of health spending systematically favours certain conditions, interventions, and populations through mechanisms that are structural rather than ideological: the lobbying power of pharmaceutical and medical device companies, the advocacy capacity of disease-specific organisations, the professional interests of medical specialists, and the political weight of the populations that benefit from specific spending allocations.
The asymmetry is not merely rhetorical. Curative medicine has organised, grateful beneficiaries and well-resourced industries behind it; prevention does not. As one analysis of public health underfunding puts it, compared to curative medicine, there are few "grateful patients" to provide financial donations, while existing special interests such as pharmaceutical firms, physicians, nursing homes, and hospitals often support increases in resources for curative care. The result is visible in the numbers: across OECD countries, spending on prevention represents only a small fraction of total health budgets, on average around 3 percent, making it the least funded component of health systems. Prevention is also held to a harsher evidentiary standard than treatment — while treatments are considered acceptable if they meet cost-effectiveness thresholds, prevention is often expected to be cost-saving before policymakers view it as a worthwhile investment, a double standard that has nothing to do with comparative health impact and everything to do with which interests are organised to defend a budget line.
The same pattern holds for hospital-based versus community-based care. Primary healthcare often remains underfunded, of poor quality, unreliable and not accountable to users, which further deprives it of funding — a self-reinforcing cycle rather than a considered allocation. Part of the reason is perceptual as much as institutional: the medical community and the wider population often associate high-quality care with specialized, technology-intensive, hospital-based services, even where the current strong bias towards specialized care poses a significant problem for system performance. In the United States, this bias is stark enough to be quantified: the country invests less than five percent of health spending in primary care, an underfunding that weakens preventive care, drives healthcare costs higher, and increases reliance on expensive emergency departments, hospitals, and specialty care.
Research investment shows the same logic applied across populations rather than across care types. Twenty-six poverty-related diseases account for fourteen percent of the global disease burden but receive only 1.3 percent of global health-related research and development expenditure, and malaria, tuberculosis, and HIV/AIDS all have shares of global research and development expenditure that are at least five times smaller than their share of global disease burden. This is not an accident of scientific opportunity; it is what happens when research funding follows purchasing power and political voice rather than burden of disease. As one assessment of the pattern concludes, this difference in rates of funding represents an injustice because it further exacerbates the disadvantages faced by Global South populations — which is precisely the point at which a political-economy description becomes a fairness claim rather than only an efficiency one.
That fairness claim needs to be stated precisely, because "unfair" is doing real work in this argument. The claim is not that any deviation from strict cost-effectiveness ranking is unjust — health systems are entitled to weigh equity, urgency, and public values alongside cost-per-outcome. The claim is narrower: an allocation is unfair when the same underlying health need is funded differently depending on the organised political weight of the population that carries it, rather than on any defensible judgement about severity, cost-effectiveness, or social priority. Political weight is not a morally relevant reason to fund one disease burden at five times the rate of another with equivalent scale. When allocation tracks lobbying capacity rather than need, the system is not making a contestable value judgement — it is letting an irrelevant variable substitute for one.
Governing Against the Political Economy
Governing health spending in ways that produce better health outcomes requires institutional mechanisms that allow evidence-based allocation to prevail against political economy pressures. Three mechanisms matter most.
The first is health technology assessment bodies that evaluate cost-effectiveness independently of commercial interests, using an explicit and consistently applied threshold rather than a double standard that varies by whether an intervention is preventive or curative. The second is budget allocation processes that require explicit justification of spending choices against population health impact criteria, so that a specialty's or a disease organisation's advocacy capacity cannot substitute for a demonstrated case that the marginal pound or dollar produces more health there than elsewhere.
The third — and the one most directly undermined by political economy pressure — is accountability mechanisms that measure health system performance against population health outcomes rather than the activity volumes and service provision metrics that are more easily measured and more responsive to political economy pressures. Activity metrics are politically convenient precisely because they reward the actors best positioned to generate them: hospitals can report admissions and procedures far more easily than a health system can report averted disease or extended healthy life expectancy in a community that never became a patient. A payment and accountability architecture built on what is easy to count will, by construction, keep funding flowing toward curative, hospital-based, well-organised care, regardless of what the evidence says about where the next unit of spending would do the most good. Outcome-based accountability is not simply a better dashboard; it is the mechanism that removes the structural advantage that activity-based measurement hands to politically powerful interests by default.
Health spending that follows the political economy rather than the evidence base is not simply inefficient — it is unfair, because it lets organised political weight stand in for health need. The health system that cannot govern against these pressures is not a health system — it is a political distribution mechanism that produces some health as a byproduct.
Discussion